These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 25588542

  • 1. Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets.
    Wu H, Sun Y, Ye H, Yang S, Lee SL, de las Morenas A.
    Pathol Oncol Res; 2015 Jul; 21(3):695-701. PubMed ID: 25588542
    [Abstract] [Full Text] [Related]

  • 2. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ, Chun SM, Kim D, Kwon H, Jang EK, Kim TY, Kim WB, Shong YK, Jang SJ, Song DE, Kim WG.
    Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
    [Abstract] [Full Text] [Related]

  • 3. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED, Martini M, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM.
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [Abstract] [Full Text] [Related]

  • 4. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
    Teng L, Deng W, Lu J, Zhang J, Ren X, Duan H, Chuai S, Duan F, Gao W, Lu T, Wu H, Liang Z.
    Oncotarget; 2017 Mar 28; 8(13):22023-22033. PubMed ID: 28423545
    [Abstract] [Full Text] [Related]

  • 5. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B, Godbert Y, Perot G, Al Ghuzlan A, Bardet S, Belleannée G, Crinière L, Do Cao C, Fouilloux G, Guyetant S, Kelly A, Leboulleux S, Buffet C, Leteurtre E, Michels JJ, Tissier F, Toubert ME, Wassef M, Pinard C, Hostein I, Soubeyran I.
    Thyroid; 2017 May 28; 27(5):682-692. PubMed ID: 28351340
    [Abstract] [Full Text] [Related]

  • 6. Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations.
    Barollo S, Pezzani R, Cristiani A, Redaelli M, Zambonin L, Rubin B, Bertazza L, Zane M, Mucignat-Caretta C, Bulfone A, Pennelli G, Casal Ide E, Pelizzo MR, Mantero F, Moro S, Mian C.
    Thyroid; 2014 May 28; 24(5):809-19. PubMed ID: 24295088
    [Abstract] [Full Text] [Related]

  • 7. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A, Costantino E, Maddalena F, Natalicchio MI, Gerardi AM, Antonetti R, Cignarelli M, Landriscina M.
    J Clin Endocrinol Metab; 2012 Jun 28; 97(6):E898-906. PubMed ID: 22442268
    [Abstract] [Full Text] [Related]

  • 8. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
    Schweiger T, Hegedüs B, Nikolowsky C, Hegedüs Z, Szirtes I, Mair R, Birner P, Döme B, Lang G, Klepetko W, Ankersmit HJ, Hoetzenecker K.
    Ann Surg Oncol; 2014 Mar 28; 21(3):946-54. PubMed ID: 24281417
    [Abstract] [Full Text] [Related]

  • 9. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
    Latteyer S, Tiedje V, König K, Ting S, Heukamp LC, Meder L, Schmid KW, Führer D, Moeller LC.
    Endocrine; 2016 Dec 28; 54(3):733-741. PubMed ID: 27696251
    [Abstract] [Full Text] [Related]

  • 10. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.
    Cancer; 2005 Jun 01; 103(11):2261-8. PubMed ID: 15880523
    [Abstract] [Full Text] [Related]

  • 11. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P, Ferrari SM, La Motta C, Materazzi G, Bocci G, Da Settimo F, Miccoli P, Antonelli A.
    Endocrine; 2016 Jul 01; 53(1):136-44. PubMed ID: 26286966
    [Abstract] [Full Text] [Related]

  • 12. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.
    Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR.
    Mol Cancer Res; 2019 May 01; 17(5):1036-1048. PubMed ID: 30733375
    [Abstract] [Full Text] [Related]

  • 13. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.
    J Clin Oncol; 2008 Dec 10; 26(35):5705-12. PubMed ID: 19001320
    [Abstract] [Full Text] [Related]

  • 14. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
    Chang YL, Yang CY, Lin MW, Wu CT, Yang PC.
    Lung Cancer; 2015 Jun 10; 88(3):254-9. PubMed ID: 25862146
    [Abstract] [Full Text] [Related]

  • 15. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.
    Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, Materazzi G, Sellari-Franceschini S, Ribechini A, Torregrossa L, Basolo F, Vitti P, Elisei R.
    Nat Rev Endocrinol; 2017 Nov 10; 13(11):644-660. PubMed ID: 28707679
    [Abstract] [Full Text] [Related]

  • 16. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
    Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, Schultz N, Berger MF, Sander C, Taylor BS, Ghossein R, Ganly I, Fagin JA.
    J Clin Invest; 2016 Mar 01; 126(3):1052-66. PubMed ID: 26878173
    [Abstract] [Full Text] [Related]

  • 17. Combination BRAFV600E Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in BRAFV600E-Mutant Anaplastic Thyroid Cancer.
    Gunda V, Ghosh C, Hu J, Zhang L, Zhang YQ, Shen M, Kebebew E.
    Thyroid; 2023 Oct 01; 33(10):1201-1214. PubMed ID: 37675898
    [Abstract] [Full Text] [Related]

  • 18. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
    Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA, Tuttle RM, Sherman E, Gill AJ, Ghossein R.
    Thyroid; 2020 Oct 01; 30(10):1505-1517. PubMed ID: 32284020
    [Abstract] [Full Text] [Related]

  • 19. Comprehensive screening for PD-L1 expression in thyroid cancer.
    Ahn S, Kim TH, Kim SW, Ki CS, Jang HW, Kim JS, Kim JH, Choe JH, Shin JH, Hahn SY, Oh YL, Chung JH.
    Endocr Relat Cancer; 2017 Feb 01; 24(2):97-106. PubMed ID: 28093480
    [Abstract] [Full Text] [Related]

  • 20. Primary squamous cell carcinoma of thyroid with a novel BRAF mutation and High PDL-1 expression: A case report with treatment implications and review of literature.
    Torrez M, Braunberger RC, Yilmaz E, Agarwal S.
    Pathol Res Pract; 2020 Oct 01; 216(10):153146. PubMed ID: 32853962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.